This webinar addresses the evolving landscape surrounding GLP-1 receptor agonists (e.g., Ozempic and Wegovy), which are being used for weight loss. With recent FDA approvals and ongoing developments, the presenters explore the legal, regulatory, and consumer-facing challenges posed by these blockbuster drugs.
